Caerulein changes morphine-induced antinociception depending on pretreatment times

Area of Science:

• Pharmacology
• Neuroscience

Background:

• Morphine is a key analgesic.
• Caerulein (CLN) is a peptide hormone.
• Interactions between CLN and morphine analgesia are not fully understood.

Purpose of the Study:

• To investigate the influence of caerulein (CLN) administration timing on morphine-induced analgesia.
• To explore the receptor mechanisms involved in CLN's modulation of morphine's effects.

Main Methods:

• Animals were pretreated with varying doses of CLN at different time points (5, 30, 60 minutes) before morphine administration.
• Antinociception was assessed using the tail-flick test.
• The effects of receptor antagonists (naloxone, sulpiride, metergoline, proglumide) on CLN-morphine interactions were evaluated.

Main Results:

• Morphine produced dose-dependent antinociception.
• Pretreatment with CLN 5 minutes before morphine decreased its analgesic effect.
• Pretreatment with CLN 30 or 60 minutes before morphine potentiated its analgesic effect.
• Naloxone, sulpiride, metergoline, and proglumide attenuated the CLN-induced potentiation of morphine analgesia.
• None of the tested agents alone affected baseline tail-flick latency.

Conclusions:

• The timing of caerulein (CLN) administration critically determines its effect on morphine analgesia, either decreasing or increasing it.
• Dopamine D-2, serotonin, and/or cholecystokinin (CCK) receptors are implicated in the potentiation of morphine analgesia by CLN.
• These findings highlight complex receptor interactions in pain modulation.